FGF5 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF5 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

FGF5 is altered in 5.88% of endometrial carcinoma patients [3].

FGF5 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF5 is altered in 0.82% of malignant solid tumor patients [3].

FGF5 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF5 is altered in 0.81% of cancer patients [3].

FGF5 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF5 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

FGF5 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGF5 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF5 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF5 is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF5 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].